Pfizer has CHMP nod for trastuzumab rival

Pfizer has received a positive opinion from the European Medicines Agency (EMA) for its biosimilar rival to Herceptin (trastuzumab), after the agency’s committee for human medicinal products (CHMP) recommended granting a marketing authorisation for the firm’s Trazimera 150mg powder for concentrate for solution for infusion.